Category Archives: Global News Feed

- Global Phase 2 placebo-controlled trial enrolled twice as fast as the industry average, establishing a roadmap for future studies -

Read more:
Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis

-- Growth to benefit ABVC’s Vitargus medical device product --FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that, according to a recent study by Bosson Research, the global Retinal Surgical Instruments market, valued at USD 1.59 billion in 2021, is expected to reach USD2.46 billion by the end of 2028, growing at a CAGR of 6.08% between 2022 and 2028.  This growth is expected to benefit ABVC’s development of its medical device, Vitargus, a gel-like substance that aims to help the eye maintain a round shape and keep the retina in place during and after retina re-attachment surgery.

See original here:
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028

TORONTO, July 18, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), the premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at Clinical Operations in Oncology Trials East Coast 2022 July 19-20 in Boston, MA.

Link:
Axiom Exhibiting at Clinical Operations in Oncology Trials East Coast 2022

SAN FRANCISCO, July 18, 2022 (GLOBE NEWSWIRE) -- Cells for Cells ("C4C"), a clinical-stage biotech pioneering allogeneic stem cell and stem-cells-derived therapeutics for high-impact chronic diseases, announced a 6-month follow-up of the groundbreaking Clinical Data from the First-ever patient dosed with an exosome-produced therapy for osteoarthritis. The results were made public at an extracellular vesicles signature series during the ISCT annual meeting in San Francisco and the ISEV meeting in Lyon, France.

See the article here:
CELLS for CELLS treats the first-ever patient with an exosome-produced therapy for osteoarthritis

Company Announcement

Read the original here:
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the...

- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 -

More here:
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022

Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis

See more here:
Codexis Announces CEO Transition Effective August 9, 2022

Menlo Park, CA, July 18, 2022 (GLOBE NEWSWIRE) --  Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to $100 million of the Company’s common stock. The subscription rights will expire and have no value if they are not exercised prior to 5:00 pm Eastern Time on August 8, 2022, the expiration date (the “Expiration Date”).

Read more:
Summit Therapeutics Announces Commencement of $100 Million Rights Offering

TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has filed articles of amendment, to effect the previously announced share consolidation (or reverse stock split) (the “Consolidation”) of its issued and outstanding common shares (the “Common Shares”) on the basis of one post-Consolidation Common Share for every twenty-five pre-Consolidation Common Shares.

View original post here:
Aeterna Zentaris Announces Effective Date of Share Consolidation

BASEL, Switzerland, July 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 9 new employees with a grant date of July 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08.

More here:
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08